1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow EGFR-Mutated Non-Small-Cell Lung Carcinoma: new trials by email Literature Review of EGFR-Mutated Non-Small-Cell Lung Carcinoma trials Research Report on EGFR-Mutated Non-Small-Cell Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors Olaparib, Durvalumab, EKG - EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2021-07-07 | 2026-09-22 |
Electrocardiography (1) · durvalumab (1) · olaparib (1)
National Cancer Institute (NCI) (1)
United States (1)